SPDL1 and melanoma: Pretreatment levels of sPD-L1 were elevated in stage IV melanoma patient sera compared with healthy donors;High pretreatment levels of sPD-L1 were associated with increased likelihood of progressive disease in patients treated by ICIs;Elevated sPD-L1 after checkpoint blocker treatment was associated with PR.